Tuberculosis News and Research

Latest Tuberculosis News and Research

PEPFAR, private partner launch 5-year 'Labs for Life' initiative

At the XIX International AIDS Conference (AIDS 2012) on Thursday, PEPFAR and Becton, Dickinson and Company (BD), "announced Labs for Life, a new collaboration to help strengthen health care and laboratory systems in the developing world along with the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (CDC)," a State Department fact sheet states.

28 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

NPR continues AIDS-related coverage on blog, programs

NPR continues its coverage of issues being discussed at the XIX International AIDS Conference (AIDS 2012) with several stories on its health blog and radio programs. On Thursday, "Tell Me More" host Michel Martin spoke with Teguest Guerma, the first woman director general of the African Medical and Research Fund (AMREF) about how African nations are responding to the HIV/AIDS epidemic and how they are working "to find the solutions ourselves, with the support of the international community," Guerma said, according to the program's transcript.

28 Jul 2012

Economist articles, blog examine research presented at AIDS 2012 conference

The Economist on Friday published two articles from Saturday's print edition regarding the XIX International AIDS Conference (AIDS 2012). One article states that "few areas of international affairs have seen more recent success than the fight against AIDS," and discusses advancements in HIV treatment research and availability.

28 Jul 2012

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Two studies presented at the XIX International AIDS Conference (AIDS 2012) and one published Wednesday in the British journal Nature "have given researchers renewed hope that a cure for AIDS may be possible," the Washington Post reports.

28 Jul 2012

Recent release: AIDS 2012 session examines possible PEPFAR, Global Fund collaboration

The Center for Global Development's "Global Health Policy" blog reports on a session at the XIX International AIDS Conference (AIDS 2012) examining "how PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria could collaborate more strategically to maximize impact."

28 Jul 2012

New platform for detecting substandard and counterfeit medicines using microfluidics

A new platform for detecting substandard and counterfeit medicines using microfluidics has been recognized with a grant from Saving Lives at Birth's "Grand Challenge through Development." Dubbed PharmaCheck, the technology is a portable, field-based tool for assessing the quality of medicines in developing countries with increased accuracy, sensitivity and reliability.

27 Jul 2012

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

TB is a leading global killer. It is the second leading infectious disease in the world, behind HIV. TB is spread through the air, so it can affect anyone, but has its worst impact on impoverished communities and those people with HIV.

27 Jul 2012

AIDS 2012 plenary speakers call for expanded efforts to provide HIV treatment, prevention to women, children

AIDS experts speaking at the XIX International AIDS Conference (AIDS 2012) on Wednesday called for an expansion of HIV care and treatment to all women instead of focusing only on those who are pregnant, the Associated Press reports.

27 Jul 2012

HPTN study results show additional benefits of early ART in HIV clinical outcomes

Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes.

27 Jul 2012

PlusNews interviews Global Fund director of country programs

In 2010, after allegations of fraud among some fund recipients in several countries, the Global Fund to Fight AIDS, Tuberculosis and Malaria convened "an independent, high-level panel to review its financial controls and how grant money is spent," and the Fund "is now implementing the panel's recommendations," PlusNews reports.

26 Jul 2012

Vienna Declaration launches ad campaign calling on U.S. presidential candidates to end 'war on drugs'

As delegates gathered for the XIX International AIDS Conference (AIDS 2012) this week in Washington, D.C., "supporters of the 2010 Vienna Declaration, which urges governments to write evidence-based drug policies," launched an ad campaign calling on U.S. President Barack Obama and Republican presidential candidate Mitt Romney "to stop the spread of AIDS by ending the so-called 'war on drugs,'" the Globe and Mail reports.

26 Jul 2012

Recent release: U.S. Census Bureau, State Department release data, maps on global HIV/AIDS

The U.S. Census Bureau on Monday launched an interactive global resource on the prevalence of HIV infection and AIDS cases and deaths, which contains 149,000 statistics, making it the "most complete of its kind in the world," according to a Census Bureau press release.

26 Jul 2012

Tips to prevent illness in crowds

Massive crowds from around the globe will mingle in London during the Olympics, and that means a world-class array of germs will mix with them. Mayo Clinic infectious diseases expert Gregory Poland, M.D., offers several tips for avoiding illness when you are around lots of people, whether at the Olympics, a professional football game, convention, arena concert or other major event.

26 Jul 2012

Children missing out on in battle against TB

The number of children diagnosed with tuberculosis only represents the tip of the iceberg, according to the University of Sydney’s Associate Professor Ben Marais, a specialist in childhood tuberculosis writing in the latest issue of The New England Journal of Medicine.

25 Jul 2012

New combination therapy for TB shows promise in Phase II study

"Results from a groundbreaking trial of three drugs given in combination -- one of them completely new and one not yet licensed for this use -- killed more than 99 percent of patients' [tuberculosis (TB)] bacteria after two weeks of treatment," and the combination "appears to be equally effective on drug-resistant TB," the Guardian reports.

25 Jul 2012

Secretary Clinton reaffirms U.S. commitment to 'AIDS-free generation,' pledges more than $150M for global efforts

In a speech delivered at the XIX International AIDS Conference in Washington, D.C., on Monday, U.S. Secretary of State Hillary Clinton "underscored the United States' commitment to achieving an 'AIDS-free generation' and announced more than $150 million in additional funding," Politico reports.

25 Jul 2012

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

A selection of editorials and op-eds from around the country that focus on the campaign to eradicate HIV.

25 Jul 2012

Recent release: Global Fund results show 3.6M people on HIV treatment under fund-supported programs

In a round-up of events from the XIX International AIDS Conference on the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Trevor DeWitt, new media communications officer for the foundation, notes that the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday released results "showing broad gains in the number of people receiving HIV treatment."

24 Jul 2012

Novel combination drug regimen could be more effective than existing treatments for TB

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet.

24 Jul 2012

Tuberculosis News and Research

Latest Tuberculosis News and Research

PEPFAR, private partner launch 5-year 'Labs for Life' initiative

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

NPR continues AIDS-related coverage on blog, programs

Economist articles, blog examine research presented at AIDS 2012 conference

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Recent release: AIDS 2012 session examines possible PEPFAR, Global Fund collaboration

New platform for detecting substandard and counterfeit medicines using microfluidics

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

AIDS 2012 plenary speakers call for expanded efforts to provide HIV treatment, prevention to women, children

HPTN study results show additional benefits of early ART in HIV clinical outcomes

PlusNews interviews Global Fund director of country programs

Vienna Declaration launches ad campaign calling on U.S. presidential candidates to end 'war on drugs'

Recent release: U.S. Census Bureau, State Department release data, maps on global HIV/AIDS

Tips to prevent illness in crowds

Children missing out on in battle against TB

New combination therapy for TB shows promise in Phase II study

Secretary Clinton reaffirms U.S. commitment to 'AIDS-free generation,' pledges more than $150M for global efforts

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

Recent release: Global Fund results show 3.6M people on HIV treatment under fund-supported programs

Novel combination drug regimen could be more effective than existing treatments for TB

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Tuberculosis News and Research

Latest Tuberculosis News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in